Kalohexis Shares 710GO Data Supporting Durable Weight Loss
NORTHBROOK, Ill., July 15, 2026 Kalohexis, Inc., a clinical-stage biotechnology company developing innovative therapies for metabolic diseases, has unveiled...
COPD
Advertisement
Bambusa Reports Promising BBT002 Data for COPD Therapy
BOSTON, June 15, 2026 Bambusa Therapeutics has announced positive preliminary multiple ascending dose (MAD) Phase 1 clinical data for...
Sino Biopharm Secures $2.1B TQC3721 AstraZeneca Agreement
HONG KONG, July 8, 2026 Sino Biopharmaceutical Limited has announced that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co.,...
Nuvaira Develops First Targeted Therapy for COPD Phenotype
MINNEAPOLIS, Minnesota, July 1, 2026 Nuvaira, Inc. has announced the first patient treated in the pivotal AIRFLOW-4 clinical trial...
Kither Biotech Completes Phase 1 Trial of KIT2014
TURIN, Italy | June 19, 2026 Kither Biotech has announced the successful completion of its first-in-human Phase 1 clinical...
Advertisements
Bambusa Therapeutics Reports Positive Phase 1 BBT002 Data at EAACI 2026
BOSTON, June 15, 2026 Bambusa Therapeutics has announced positive preliminary results from the multiple ascending dose (MAD) cohorts of...
Kelun-Biotech and Windward Bio Advance SKB378 in COPD
CHENGDU, China – June 9, 2026 Kelun-Biotech has announced that its partner Windward Bio has successfully dosed the first...
Altesa’s Vapendavir Shows Promise in Preventing COPD Flares
WASHINGTON, D.C., June 5, 2026 Altesa BioSciences has unveiled encouraging new Phase 2 clinical findings demonstrating that vapendavir, its...
GSK Expands Arexvy Approval for At-Risk Adults
LONDON, United Kingdom, May 20, 2026 GSK has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved...
Regeneron Expands Precision Medicine Pipeline With $2.3B Parabilis Collaboration
TARRYTOWN, N.Y., May 18, 2026 Regeneron Pharmaceuticals has announced a major strategic collaboration with Parabilis Medicines valued at up...
Advertisement
